VLP Therapeutics
VLP Therapeutics is a Maryland-based biotechnology company established in 2012, focused on developing preventative and therapeutic vaccines as well as targeted antibody agents for cancer, infectious diseases, autoimmune conditions, and neurological diseases. The company utilizes next-generation virus-like particle platforms, gene delivery systems, and structure-based antigen design to address unmet global medical needs. Its research pipeline includes vaccine candidates for malaria, dengue, COVID-19, and cancer immunotherapies. The organization is driven by a team with experience in vaccine R&D, clinical development, and collaborative partnerships with prominent academic and government institutions.
Industries
N/A
VLP Therapeutics
704 Quince Orchard Rd., Suite 110, Gaithersburg, MD 20878, United States
Patents
Alphavirus replicon encoding chimeric SARS-CoV-2 receptor binding domains
2025-04-22 • US-12280102-B2
View DetailsAlphavirus replicon vector and immunotherapy by administering same
2024-11-05 • US-12134777-B2
View DetailsChikungunya virus (CHIKV) or Venezuelan equine encephalitis virus (VEEV) virus-like particles comprising heterologous antigens inserted into the envelope protein
2022-05-31 • US-11345726-B2
View DetailsVirus like particle comprising PD-1 antigen or PD-1 ligand antigen
2019-11-05 • US-10464986-B2
View Details
Alphavirus replicon encoding chimeric SARS-CoV-2 receptor binding domains
2025-04-22 • US-12280102-B2
View DetailsAlphavirus replicon vector and immunotherapy by administering same
2024-11-05 • US-12134777-B2
View DetailsChikungunya virus (CHIKV) or Venezuelan equine encephalitis virus (VEEV) virus-like particles comprising heterologous antigens inserted into the envelope protein
2022-05-31 • US-11345726-B2
View DetailsVirus like particle comprising PD-1 antigen or PD-1 ligand antigen
2019-11-05 • US-10464986-B2
View DetailsExpertise Areas
- Vaccine platform engineering
- Immunotherapy development
- Infectious disease vaccines
- Cancer vaccines
Key Technologies
- Virus-like particle technology
- Self-amplifying RNA (saRNA)
- Modified nucleoside incorporation
- Gene delivery systems
Key People
Co-Founder, Director, and Chief Executive Officer
Co-Founder, Director, and General Counsel
Co-Founder and IP Counsel
Chief Scientific Officer
Director
Co-Founder, Director, and Chief Executive Officer
Co-Founder, Director, and General Counsel
Co-Founder and IP Counsel
Chief Scientific Officer
Director
News & Updates
Received a two-year grant from a global health foundation to develop multi-stage malaria vaccines.
Chosen as a recipient of Japanese government funding to support COVID-19 vaccine program.
Awarded funding by the GHIT Fund for a Phase I clinical trial of dengue virus-like particle vaccines.
Received US Patent covering flavivirus virus-like particle technology underpinning dengue vaccine development.
Awarded a Maryland Industrial Partnership grant to advance malaria vaccine program and conduct a first-in-human phase I/IIa clinical study.
Awarded $2.4 million from the U.S. Army Medical Research Program toward malaria vaccine development.
Received a two-year grant from a global health foundation to develop multi-stage malaria vaccines.
Chosen as a recipient of Japanese government funding to support COVID-19 vaccine program.
Awarded funding by the GHIT Fund for a Phase I clinical trial of dengue virus-like particle vaccines.
Received US Patent covering flavivirus virus-like particle technology underpinning dengue vaccine development.
Awarded a Maryland Industrial Partnership grant to advance malaria vaccine program and conduct a first-in-human phase I/IIa clinical study.
Awarded $2.4 million from the U.S. Army Medical Research Program toward malaria vaccine development.